Easy to see the cost benefits of time-limited therapy with venetoclax-obinutuzumab(Gazyva).
source:
3-year cost comparison of novel agents/combos - CLL Support
3-year cost comparison of novel agents/combos
Written by
avzuclav
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
Revisiting Richter transformation in the era of novel CLL agents
will lead to improved treatment and prognosis....
Sequential And Combination Treatments With Novel Agents (Oct. 2019)
or if they should preferably be combined in time-limited treatment regimens aiming at deep and...
Resistance-Associated Mutations in CLL Patients Treated With Novel Agents
gene were detected in patients who had failed on venetoclax.
For 20% of patients, the ibrutinib...
CLL FCR update - 3 years on.
negative status on FCR have an 80% chance at achieving 15+ years of progression free survival. See...
CLL Society/ CAR-T! Read the story of Dr. Brian Koffman's 3 years of durable remission post-CAR-T!
